Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Ireland’s Data Protection Commission Launches GDPR Investigation Into X’s AI Chatbot Grok 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years 
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
BHP Group Half-Year Profit Surges as Copper Overtakes Iron Ore on AI-Driven Demand 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
NEW YORK, NY, May 02, 2018 -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it will be presenting at the 3rd annual Disruptive Growth & Healthcare Conference on Tuesday, May 8th at 12:50pm EDT. Tom LaVoy, CEO of IsoRay, will be presenting as well as meeting with investors.
Tom LaVoy, IsoRay’s CEO, will also be a participant on a panel discussion at 1:45pm EDT entitled “Disruptive Injectables & Oncology”.
The 2018 Disruptive Growth & Healthcare Conference will offer the exclusive opportunity to discover life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies and business models.
For those interested in attending, please visit www.DisruptNYC.com for more information.
About IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay. Follow us on Twitter@IsoRay.
About RHK Capital:
Advisory Group Equity Services, Ltd. (dba RHK Capital) was founded in 1984. RHK Capital is a boutique investment banking firm specializing in small to medium-sized transactions. RHK is led by a management team with extensive financial industry experience and a desire to provide companies and individuals with the tools and expertise to accomplish their financial goals. In addition to investment banking, RHK has grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, investment management, mortgages, and business lending. As a division of Advisory Group Equity Services (AGES), all securities are offered through Advisory Group Equity Services Ltd., a registered broker-dealer, member of the Financial Industry Regulatory Authority and the Securities Investor Protection Corporation.
Contacts: IsoRay Inc. [email protected] (509) 375-1202 Investors: Stephanie Prince, Managing Director PCG Advisory Group [email protected] (646) 762-4518
